Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.
about
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 BlockadeImproved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCsCD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
P2860
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Intravenously usable fully ser ...... ler of dendritic cell therapy.
@en
type
label
Intravenously usable fully ser ...... ler of dendritic cell therapy.
@en
prefLabel
Intravenously usable fully ser ...... ler of dendritic cell therapy.
@en
P2093
P2860
P921
P1433
P1476
Intravenously usable fully ser ...... ler of dendritic cell therapy.
@en
P2093
Andre Lieber
Hongjie Wang
Lotta Vassilev
Mikko Siurala
Otto Hemminki
Riikka Havunen
Sadia Zafar
Silvio Hemmi
Simona Bramante
Siri Tähtinen
P2860
P304
P356
10.1080/2162402X.2016.1265717
P577
2016-12-07T00:00:00Z